| __timestamp | Alnylam Pharmaceuticals, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 5496000 |
| Thursday, January 1, 2015 | 60610000 | 9786000 |
| Friday, January 1, 2016 | 89354000 | 6792000 |
| Sunday, January 1, 2017 | 199365000 | 7313000 |
| Monday, January 1, 2018 | 382359000 | 8382000 |
| Tuesday, January 1, 2019 | 479005000 | 10803000 |
| Wednesday, January 1, 2020 | 588420000 | 12944000 |
| Friday, January 1, 2021 | 620639000 | 21967000 |
| Saturday, January 1, 2022 | 770658000 | 32810000 |
| Sunday, January 1, 2023 | 795646000 | 46542000 |
| Monday, January 1, 2024 | 975526000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, understanding the financial strategies of key players is crucial. Alnylam Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion and investment in market presence. This growth underscores Alnylam's commitment to scaling its operations and enhancing its market footprint.
In contrast, Xenon Pharmaceuticals Inc. exhibited a more measured increase of approximately 750% in SG&A expenses during the same period. This steady rise indicates a strategic, albeit cautious, approach to growth, focusing on sustainable development and operational efficiency.
These trends highlight the differing strategies of two innovative companies in the pharmaceutical sector, offering insights into their operational priorities and market strategies.
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Zoetis Inc. vs Xenon Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Xenon Pharmaceuticals Inc. vs MannKind Corporation
Breaking Down SG&A Expenses: Xenon Pharmaceuticals Inc. vs Wave Life Sciences Ltd.
Comparing SG&A Expenses: Xenon Pharmaceuticals Inc. vs Galapagos NV Trends and Insights